Q1 Earnings Forecast for MaxCyte Issued By William Blair

MaxCyte, Inc. (NASDAQ:MXCT) – Equities research analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a research note issued on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will earn ($0.09) per share for the quarter. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.30) EPS.

A number of other research firms also recently weighed in on MXCT. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus cut their price target on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday.

MaxCyte Stock Up 7.5 %

NASDAQ:MXCT opened at $3.29 on Thursday. The company has a market cap of $348.61 million, a P/E ratio of -9.68 and a beta of 1.35. MaxCyte has a fifty-two week low of $2.76 and a fifty-two week high of $5.26. The firm’s 50 day moving average is $4.17 and its two-hundred day moving average is $3.97.

Institutional Investors Weigh In On MaxCyte

A number of large investors have recently added to or reduced their stakes in MXCT. Mirabella Financial Services LLP acquired a new stake in MaxCyte during the 4th quarter valued at $15,392,000. River Global Investors LLP grew its holdings in MaxCyte by 57.7% during the 4th quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock valued at $13,494,000 after purchasing an additional 1,190,630 shares in the last quarter. Cadian Capital Management LP grew its holdings in MaxCyte by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company’s stock valued at $38,873,000 after purchasing an additional 1,155,476 shares in the last quarter. AXA S.A. acquired a new stake in MaxCyte during the 4th quarter valued at $4,105,000. Finally, Royce & Associates LP grew its holdings in MaxCyte by 146.9% during the 4th quarter. Royce & Associates LP now owns 799,873 shares of the company’s stock valued at $3,327,000 after purchasing an additional 475,949 shares in the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.